Association of Self-Reported Systemic Reactions Following SARS-CoV-2 Vaccination With Immunological Response in The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 Vaccines (ENFORCE)

Media type: E-Article
Title: Association of Self-Reported Systemic Reactions Following SARS-CoV-2 Vaccination With Immunological Response in The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 Vaccines (ENFORCE)
Contributor: Bannister, Wendy P; Raben, Dorthe; Valentiner-Branth, Palle; Tolstrup, Martin; Larsen, Lykke; Tarp, Britta; Brouw Iversen, Mette; Schmeltz Søgaard, Ole; Rye Ostrowski, Sisse; Breinholt Stærke, Nina; Jakobsen, Marie Louise; Lindvig, Susan Olaf; Juhl, Maria Ruwald; Somuncu Johansen, Isik; Mustafa, Ahmed B; Østergaard, Lars; Dam Larsen, Fredrikke; Surland Knudsen, Lene; Klastrup, Vibeke; Wiese, Lothar; Benfield, Thomas; Toft Petersen, Kristine; Iversen, Kasper K; Nielsen, Henrik; [...]
imprint: Oxford University Press (OUP), 2023
Published in: Open Forum Infectious Diseases
Language: English
DOI: 10.1093/ofid/ofad248
ISSN: 2328-8957
Keywords: Infectious Diseases ; Oncology
Origination:
Footnote:
Description: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Side effects to SARS-CoV-2 vaccines are a key concern contributing to vaccine hesitancy, but more individuals may be encouraged if they were known to lead to a stronger immune response.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Adult participants were included from the Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 Vaccines (ENFORCE), who completed a questionnaire to assess systemic reactions following SARS-CoV-2 vaccination (BTN162b2, mRNA-1273, ChAdOx1) and had SARS-CoV-2 spike IgG levels measured at baseline and post-vaccine. A symptom score was developed to measure severity of systemic adverse reactions (+1 for each moderate, +2 for each severe). Post-vaccination SARS-CoV-2 spike IgG levels were compared between participants with different scores using multivariable linear regression.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>A total of 6528 participants were included (56.3% females, median age 64 years [IQR 54-75]). After first vaccination, no association was found between symptom score and post-vaccine dose spike IgG level (p-value=0.575). Following second vaccination, significantly higher spike IgG levels were observed according to higher symptom score (p&lt;0.001); adjusted geometric mean ratios (95% CIs) were 1.16 (1.04-1.30), 1.24 (1.09-1.41), 1.25 (1.06-1.46), and 1.21 (1.08-1.35), for scores of 2, 3, 4, ≥5, respectively, compared to a score of 0. After adjustment for pre-vaccine dose spike IgG, this association was attenuated.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>An association was found between more severe adverse reactions and stronger antibody response after the second vaccination but not the first, likely attributed to higher levels of pre-existing immunity gained from response to first vaccination. Regardless of side effects, most people experienced an effective immune response following vaccination.</jats:p> </jats:sec>
Access State: Open Access

Search in field:

Recently searched for: